BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript Summary
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript Summary
G&A expenses rose to $3.2 million in Q3 2024, from $2.2 million in the same quarter the previous year, reflecting higher costs related to the acquisition of Adaptive Phage Therapeutics.The following is a summary of the BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript:
以下是biomx公司（PHGE）2024年第三季度業績會記錄的摘要：
Financial Performance:
財務表現：
Cash, cash equivalents, and short-term deposits totaled $24.7 million as of September 30, 2024, down from $30.7 million as of December 31, 2023.
R&D expenses increased to $7.3 million in Q3 2024, up from $5.6 million in Q3 2023, mainly due to preparations for the Phase 2b trial of BX004 and clinical trial expenses for BX211.
G&A expenses rose to $3.2 million in Q3 2024, from $2.2 million in the same quarter the previous year, reflecting higher costs related to the acquisition of Adaptive Phage Therapeutics.
Net income reached $9.6 million in Q3 2024, a significant turnaround from a net loss of $7.9 million in Q3 2023.
截至2024年9月30日，現金、現金等價物和短期存款總額爲2470萬，較2023年12月31日的3070萬有所減少。
2024年第三季度的研發支出增至730萬，較2023年第三季度的560萬有所增加，主要是由於BX004的20億試驗準備和BX211的臨床試驗費用。
2024年第三季度的總務及行政費用爲320萬，相較於去年同季度的220萬有所上升，反映了與收購Adaptive Phage Therapeutics相關的成本增加。
2024年第三季度淨利潤達到960萬，顯著扭轉了2023年第三季度的790萬淨虧損。
Business Progress:
業務進展:
BiomX completed patient enrollment for the Phase 2 trial of BX211 for diabetic foot osteomyelitis (DFO), with top line results expected in Q1 2025.
Presented positive safety and efficacy results from the BX004 Phase 1b/2a trial at major scientific conferences.
Expects to report top line results for the BX004 Phase 2b study in H1 2026 due to manufacturing delays now resolved.
biomx已完成BX211用於糖尿病足骨髓炎（DFO）第二階段試驗的患者入組，預計在2025年第一季度公佈頂線結果。
在主要科學會議上展示了BX004 1b/2a期試驗的積極安全性和有效性結果。
由於現在已解決的製造延遲，預計將在2026年上半年報告BX004 20億研究的主要結果。
Opportunities:
機會：
The ongoing development and potential of phage-based therapies in addressing antibiotic-resistant infections and associated conditions like DFO and cystic fibrosis.
正在開發和潛在的基於噬菌體的療法，以應對抗生素耐藥性感染以及與之相關的疾病，如DFO和囊性纖維化。
Risks:
風險：
The initial slow progression and the potential delays in the clinical development timeline for BX004 due to scaling of manufacturing process.
由於製造過程的規模化，BX004的臨床開發時間表初期進展緩慢，並可能出現延遲。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
